Back to Glossary

    Regulatory & Documentation

    Clinical Trial Protocol

    A clinical trial protocol is the master document that defines a clinical study's objectives, design, methodology, statistical considerations, and operational conduct, and that all investigators must follow to ensure scientific validity and participant safety.

    A clinical trial protocol is required by every regulatory authority (FDA, EMA, PMDA, MHRA) before a study may enroll participants. It functions as both a scientific blueprint and an operational contract: it specifies the research question, the study population (via inclusion and exclusion criteria), the intervention, the comparator, the endpoints, the schedule of assessments, the statistical analysis plan summary, and the safety reporting framework.

    Modern protocols are governed by ICH E6(R3) Good Clinical Practice and, structurally, by ICH M11 (the Common Protocol Template), which standardizes section ordering and machine-readable elements. A well-designed protocol minimizes amendments downstream; protocol amendments are the single largest source of avoidable cost and delay in trial startup, with a median amendment costing sponsors USD 535,000 and adding ~3 months to the timeline (Tufts CSDD).

    AI-assisted protocol authoring (such as Kitsa's KScribe Clinical Studio) reduces amendment risk by enforcing internal consistency between objectives, endpoints, eligibility, and statistical sections; flagging operationally infeasible criteria; and benchmarking design choices against historical trials in the same indication.

    References

    Related terms

    See how Kitsa applies this in your trials

    Kitsa's agentic AI compresses protocol development, site selection, and patient pre-screening from months into weeks.

    Request a demo